COMMUNIQUÉS West-GlobeNewswire

Geron Appoints Two New Independent Board Members
28/03/2019
MENLO PARK, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its Board of Directors. In [...]
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
28/03/2019
ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company) , a developer and provider of advanced solutions in the treatment of substance abuse disorders, today [...]
Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference
28/03/2019
BOSTON, March 28, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
Passage Bio Appoints Saqib Islam to Board of Directors
28/03/2019
PHILADELPHIA, March 28, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases, today announced the [...]
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates
28/03/2019
Investigational New Drug Application Cleared for First-Ever Red Cell Therapeutic™, RTX-134, for Treatment of Phenylketonuria Data from Company’s Oncology Pipeline to be Presented at AACR 2019 Annual Meeting CAMBRIDGE, [...]
Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
28/03/2019
SANTA MONICA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced [...]
Molecular Templates Announces Initiation of Phase II Monotherapy Study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
28/03/2019
Study Update Expected in 2H19 with Final Data Expected in 2020 AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the [...]
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
28/03/2019
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, [...]
Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)
28/03/2019
Full inarigivir (IRIG) 200mg cohort results to be presented as a late breaker oral presentation at General Session II and Award Ceremony I Poster presentation to describe the antiviral activity of IRIG in HBV clinical [...]
Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD
28/03/2019
400 mg dose reached statistical significance compared to placebo, consistent with previous Phase III studies: • Change versus baseline in ADHD Rating Scale 5, p-value = 0.0082 • Effect size of 0.66 • CGI-I secondary [...]
Todos Medical to Present at Two Upcoming Investor Conferences
28/03/2019
Management to Provide Corporate Overview and Participate in One-on-One Meetings REHOVOT, Israel, March 28, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company [...]
Spectral Announces Fourth Quarter and Fiscal 2018 Results
28/03/2019
TORONTO, March 28, 2019 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX: EDT) , a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its [...]
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
28/03/2019
Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI [...]
Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting
28/03/2019
EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]
Inivata Completes $52.6m (£39.8m) Series B Funding Round
28/03/2019
Inivata Completes $52.6m (£39.8m) Series B Funding Round Funds will accelerate commercialization of InVisionFirst TM -Lung Liquid Biopsy test and the development of the InVision ® liquid biopsy platform into new [...]
Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited
28/03/2019
BUFFALO, N.Y., March 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
28/03/2019
- Data highlight potential of Fc multimerization technology platform to significantly enhance the potency and efficacy of therapeutic antibodies - CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Momenta [...]
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
28/03/2019
- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial in Multiple Myeloma - - First Solid Tumor Trial [...]
Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
28/03/2019
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]

Pages